SCHEMBL2194871

SCHEMBL2194871

O=[N+]([O-])c1ccc(O)nc1Nc1ccccc1OC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
EPHX2 P34913 1/20 0.44
C1R P00736 1/20 0.41
AURKA O14965 1/20 0.41
MAPK1 P28482 3/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 3/20 0.38
MAPT P10636 3/20 0.38
AKR1C3 P42330 2/20 0.38
AKR1C2 P52895 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 1/20 0.38
CXCR2 P25025 1/20 0.37
PRKCQ Q04759 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
AKR1B1 P15121 1/20 0.37
AKR1C4 P17516 1/20 0.37
AKR1C1 Q04828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195864 0.86 FGFR4 (0.50) L3MBTL1MEN1KMT2AEPHX2C1R
SCHEMBL2194289 0.81 ALDH1A1 (0.46) L3MBTL1MEN1KMT2AEPHX2AURKA
SCHEMBL2198338 0.80 L3MBTL1 (0.44) L3MBTL1MEN1KMT2AEPHX2C1R
SCHEMBL2197093 0.80 MEN1 (0.46) L3MBTL1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL2193785 0.79 EPHX2 (0.49) MEN1KMT2AEPHX2C1RAURKA
SCHEMBL2195443 0.79 PRKCQ (0.39) L3MBTL1MEN1KMT2AAURKAMAPK1
SCHEMBL4055027 0.78 MAPK1 (0.53) L3MBTL1MEN1KMT2AEPHX2C1R
SCHEMBL2191393 0.77 CXCR2 (0.44) L3MBTL1MEN1KMT2AMAPK1ALDH1A1
SCHEMBL2196630 0.77 MAPK1 (0.55) L3MBTL1MEN1KMT2AC1RMAPK1
SCHEMBL2192755 0.77 KMT2A (0.51) L3MBTL1MEN1KMT2AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 L3MBTL1 4688/4885MEN1 2445/4885KMT2A 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.